Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is currently in a reset year, with revenue guidance for FY26 missing consensus by 6% at the midpoint. However, incremental clarity on DOS-related ARR churn and potential retention of $22M out of a $52M pool indicate potential revenue growth in FY27. Additionally, the potential sale of certain application assets, such as VitalWare, could generate significant proceeds and support the company's financials.

Bears say

Health Catalyst is facing several near-term challenges, including a decline in revenue and profitability due to the completion of its DOS-to-Ignite migration and potential customer churn and down-selling. However, the company's long-term potential lies in its proprietary technology and data analytics, which can help address the $1 trillion in healthcare waste in the US. While the transition to Ignite has led to some pressure on the data platform, the company has already shown some traction with new platform customer signings. The risk of potential churn and down-selling highlights the need for effective execution and management of resources to drive growth and improve profitability in the future.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.